Alaunos' ALN1003 Shows Up to 30.5% Weight Loss, Broad Metabolic Gains in Preclinical Obesity Study
TCRT sits 49% above its 52-week low of $1.67 on light trading volume (0.3× avg).
Summary
Alaunos Therapeutics announced compelling preclinical results for its obesity drug candidate, ALN1003, in obese mouse studies. The data showed significant body weight reductions, including up to 30.5% in one study, alongside favorable body composition shifts and improvements in insulin resistance and liver health. This positive development for its lead candidate is critical for the company, which is currently facing severe financial challenges, including a going concern warning and Nasdaq non-compliance. These strong results could be instrumental in attracting future partnerships or securing necessary financing.
At the time of this announcement, TCRT was trading at $2.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.8M. The 52-week trading range was $1.67 to $6.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.